Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

• Main Authors: Stefania Chiappini (Author), Rachel Vickers-Smith (Author), Daniel Harris (Author), G. Duccio Papanti Pelletier (Author), John Martin Corkery (Author), Amira Guirguis (Author), Giovanni Martinotti (Author), Stefano L. Sensi (Author), Fabrizio Schifano (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to <i>semaglutide</i>, a glucagon-like peptide-1 (...